After a 17-year partnership, BNP Paribas is looking to acquire up to 100% of Exane, raising its stake from the 50% currently held.
The French bank is seeking to ‘further strengthen and widen the range of cash equity and derivatives services’ it offers to institutional investors and corporates globally, and leverage the acquisition of Deutsche Bank’s Global Prime Finance and Electronic Equities business in 2019 to position the bank as a leading provider in global equities. Exane is a small player in the public offering space and has just over 275 live products worth an estimated US$364m across markets incl
Continue reading and get unlimited access for 7 days with a free trial of SRP.
Get a free trialAlready a subscriber? Login